6 results about "Jatrorrhizine" patented technology

The application belongs to the technical field of biological medicine, and specifically discloses application of jatrorrhizine in preparation of a medicine for preventing and treating intestinal radiation injury, and a medicine for preventing and treating intestinal radiation injury.The application verifies the effect of jatrorrhizine on resisting intestinal radiation injury by using an intestinal organ model, wherein the jatrorrhizine can obviously improve the changes in survival rate, bud number and organ size of the intestinal organ caused by radiation injury, and eliminate the adverse effects caused by the intestinal radiation injury.After abdominal irradiation injury of experimental mice, jatrorrhizine is injected into the abdominal cavity, the intestinal length is obviously increased, the survival rate is improved, and HE staining of small intestinal sections shows that the crypt depth and villus structure are improved.It is proved that the jatrorrhizine can promote the regeneration and repair of the intestinal organ after radiation, improve the survival rate, and improve the morphological changes of the intestinal caused by radiation injury.The medicine containing the jatrorrhizine provided by the application can improve the intestinal lesions caused by radiation injury, relieve the intestinal injury symptoms, and improve the survival rate of individuals.

The invention discloses preparation and application of a novel magnolol and jatrorrhizine conjugate, relates to the technical field of medicines, and aims to overcome the defects of poor drug resistance and insufficient activity of a single-target anti-cancer drug. According to the technical scheme, acetone or acetonitrile is used as a solvent, and through a two-step substitution reaction, the magnolol and jatrorrhizine conjugate is obtained; the preparation method comprises the following steps: reacting magnolol with dibromo-alkane to generate an intermediate B, and conjugating the intermediate B with jatrorrhizine to obtain a final product with a general formula C; or the jatrorrhizine reacts with dibromo alkane to generate an intermediate E, and then the intermediate E is conjugated with magnolol to obtain the final product of the general formula C. In the preparation process, reaction conditions (such as potassium carbonate alkaline environment and 82 DEG C reflux) are optimized, and high yield and purity are realized. The conjugate disclosed by the invention is widely applied to the anti-tumor field, has remarkable inhibitory activity on various cancer cells (such as non-small cell lung cancer cells HCC827 and human lung adenocarcinoma cells H1975), has better effects than magnolol and jateorhizine monomers, and provides a new candidate for research and development of multi-target drugs.

The invention discloses application of coptis chinensis active ingredient jateorhizine in preparation of a medicine for resisting EGFR-TKIs drug-resistant non-small cell lung cancer. The invention provides a novel application of jateorhizine serving as an active ingredient of traditional Chinese medicine rhizoma coptidis in resisting non-small cell lung cancer, and finds that the jateorhizine can obviously inhibit growth, proliferation, migration and invasion of H1975 cells, and as the concentration of the jateorhizine is increased, the apoptosis rate of the H1975 cells is gradually increased, the invasion ability is gradually weakened, and the jateorhizine has concentration dependence. The jatrorrhizine intervenes in the T790M mutant EGFR-TKIs drug-resistant non-small cell lung cancer through a PI3K-Akt signal channel, and further kills targeted drug-resistant non-small cell lung cancer cells by adjusting the activity of tyrosine, serine and other amino acid kinases, adjusting the cell cycle and the like. The jatrorrhizine provided by the invention has the effect of intervening in the targeted drug-resistant non-small cell lung cancer, provides a new direction for the treatment of the targeted drug-resistant non-small cell lung cancer, and also provides a new thought for the research of traditional Chinese medicines.

The invention discloses application of jatrorrhizine in preparation of a medicine for preventing and treating mycoplasma hyopneumoniae infection, and belongs to the field of microbial infectious diseases and medicines. Researches find that jatrorrhizine shows good in-vitro anti-mycoplasma activity and has a remarkable bactericidal effect; the jatrorrhizine is extremely low in cytotoxicity and good in safety, can improve the survival of mycoplasma hyopneumoniae infected cells and inhibit the release of inflammatory factors of the infected cells, and shows broad-spectrum anti-inflammatory activity; the jatrorrhizine can remove pathogens in tissues, control body temperature fluctuation, recover normal growth performance of infected pigs and remarkably improve lung tissue lesions and inflammatory pathological injuries caused by infection. The invention provides the application of jateorhizine in preparing the medicine for preventing or treating mycoplasma hyopneumoniae infection, and the jateorhizine serving as an anti-mycoplasma medicine which is natural in source, high in safety and exact in curative effect has an application prospect and an important clinical value in treating the mycoplasma hyopneumoniae infection as an antibiotic substitute.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a UHPLC-QE-MS method for separating and determining fingerprint components in a traditional Chinese medicine composition. The traditional Chinese medicine composition consists of the following components in parts by mass: 1-5 parts of leech and 0.5-2.5 parts of ligusticum wallichii. The fingerprint component is prepared from any one or more of saikoside D3, jatrorrhizine, palmatine, (+)-zearalene, oroxylin A, epiberberine, acacetin, genistein, timosaponin B II and tangeretin. According to the method, octadecyl silane bonded silica gel is used as a chromatographic column filler, a 0.05-0.5% formic acid aqueous solution is used as a mobile phase A, a 0.05-0.5% formic acid acetonitrile solution is used as a mobile phase B, fingerprint components in the traditional Chinese medicine composition are separated through linear elution gradient, and mass spectrometry is adopted for detection. Based on the method, the quality consistency and stability of the preparation can be effectively monitored, and support is provided for quality control of the preparation.

The application discloses a method for simultaneously determining the contents of 12 components in Longqing capsules by HPLC. The method comprises simultaneously determining the contents of paeoniflorin, paeonol, chlorogenic acid, caffeic acid, berberine hydrochloride, coptisine, jatrorrhizine hydrochloride, gallic acid, rutin, kaempferol, luteolin and phellodendrine hydrochloride in the Longqing capsules, gradient elution is carried out by adopting a chromatographic column with octadecylsilane-bonded silica gel as a filler, 0.1% phosphoric acid as mobile phase A and a methanol solution as mobile phase B, the column temperature is 35 DEG C, and the detection wavelength is 270 nm, and the HPLC content determination method is established, so that a multi-index quality control method of the Longqing capsules is established. The method is simple, stable and reliable, has high detection efficiency, and has reference value for establishing the quality standard and control system of the Longqing capsules based on the theory of traditional Chinese medicine.